How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

Einsele H, Ljungman P, Boeckh M (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Blood American Society of Hematology

Book Volume: 135

Pages Range: 1619-1629

Journal Issue: 19

DOI: 10.1182/BLOOD.2019000956

Abstract

Cytomegalovirus (CMV) reactivation remains one of the most common and life-threatening infectious complications following allogeneic hematopoietic stem cell transplantation, despite novel diagnostic technologies, several novel prophylactic agents, and further improvements in preemptive therapy and treatment of established CMV disease. Treatment decisions for CMV reactivation are becoming increasingly difficult and must take into account whether the patient has received antiviral prophylaxis, the patient's individual risk profile for CMV disease, CMV-specific T-cell reconstitution, CMV viral load, and the potential drug resistance detected at the time of initiation of antiviral therapy. Thus, we increasingly use personalized treatment strategies for the recipient of an allograftwith CMV reactivation based on prior use of anti-CMV prophylaxis, viral load, the assessment of CMV-specific T-cell immunity, and the molecular assessment of resistance to antiviral drugs.

Involved external institutions

Universitätsklinikum Würzburg DE Germany (DE) Karolinska University Hospital / Karolinska Universitetssjukhuset SE Sweden (SE) Fred Hutchinson Cancer Research Center US United States (USA) (US)

How to cite

APA:

Einsele, H., Ljungman, P., & Boeckh, M. (2020). How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood, 135(19), 1619-1629. https://doi.org/10.1182/BLOOD.2019000956

MLA:

Einsele, Hermann, Per Ljungman, and Michael Boeckh. "How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation." Blood 135.19 (2020): 1619-1629.

BibTeX: Download